Personalis (PSNL) Stock

PSNL stock has surged from $1.61 to over $4.00 per share following strong Q2 earnings and increased demand for NeXT Personal MRD test. Personalis reported $22.6M in revenue for Q2, with improved gross margins and increased full-year revenue guidance. Personalis secured Medicare coverage, expanded commercial partnerships, showcased product benefits, settled an IP lawsuit, and strengthened market position.

Personalis (PSNL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.

SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company's freedom to operate in the MRD market and broadens patient access to the benefits of MRD testing.

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal®, Personalis' ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal residual disease (MRD) and recurrence in cancer. Members of Tempus' commercial team can now engage in discussions with doctors about the use of the NeXT Personal Dx test for breast and lung can.

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring data for the company's NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which convenes from May 31-June 4, 2024, in Chicago, Illinois. “As the body of studies continue.

Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript

Personalis, Inc. (NASDAQ:PSNL ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich Chen - Chief Medical Officer and EVP, Research and Development Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Mark Massaro - VTIG Swayampakula Ramakanth - H.C. Wainwright Operator Good afternoon and welcome to Personalis Third Quarter 2023 Earnings Conference Call.

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2023 financial results on Wednesday, May 3, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.